The new LEO Foundation Skin Immunology Research Center at the University of Copenhagen will pave the way to a better understanding, prevention and treatment of skin diseases that plague a quarter of the world's population.
Although several new melanoma treatments have shown promise, none replaces surgery as the primary therapy yet, according to updated guidelines from the American Academy of Dermatology (AAD).
Leg ulcers can be caused by vasculitis, pressure sores, inflammatory diseases, traumatic injuries, and cutaneous neoplasms which are often misdiagnosed as skin ulcers, write Lidia Sacchelli and colleagues in the September 19 online issue of the Journal Dermatopathology
A novel topical minocycline foam has been found to significantly reduce both inflammatory and noninflammatory lesions and improve acne scares in patients with moderate-to-severe acne vulgaris in phase three clinical trials.
The number of actinic keratosis lesions treated in the Medicare population increased by about 20 percent between 2007 and 2015, according to a billing claims analysis. However, during the same time period, the mean inflation-adjusted payments per 1,000 Medicare Part B fee-for-service beneficiaries decreased from $11,749 to $10,942, due to reimbursement reductions to control the rising costs of actinic keratosis treatment.
A review of more than 5,000 patients with moderate to severe plaque psoriasis who were treated with ixekizumab over three years, shows no unexpected safety signals. The review, published in the September issue of the Journal of European Academy of Dermatology & Venereology, examines treatment-associated adverse effects.
Facial massaging using a roller can increase skin blood flow for more than ten minutes after the massage. It can also improve vasodilation — the widening of blood vessels, — in the long-term, according to a study by researchers in Japan.
Purdue University researchers have developed a new flexible and translucent base for silicon nanoneedle patches to deliver exact doses of biomolecules directly into cells and expand observational opportunities.
A review of more than 5,000 patients with moderate to severe plaque psoriasis who were treated with ixekizumab over three years, shows no unexpected safety signals. The study was published in the Journal of the European Academy of Dermatology & Venereology, examines treatment-associated adverse effects.
Psoriasis appears to be significantly associated with inflammatory bowel disease (IBD). The study was published in JAMA Dermatology. Researchers assessed case-control, cross-sectional, or cohort studies that examined either the odds or risk for IBD in patients with psoriasis.
New guidelines have been released for the treatment of primary cutaneous melanoma, according to a report from the American Academy of Dermatology published online Nov. 1 in the Journal of the American Academy of Dermatology. Researchers reviewed the evidence and made treatment recommendations for patients with primary cutaneous melanoma.
Think of the protein BH3 like a finger that turns off to cancer cell survival switch. The problem is that most cancer cells have found ways to remove this "finger commonly, by breaking the action of a gene called p53 that puts the BH3 finger in motion.
Now think of Bcl-2 as the switch itself. When cancer breaks p53, the BH3 finger never moves, and the Bcl-2 survival switch remains on. Despite thousands of published studies, researchers have not had much luck directly protecting the action of p53. But, BH3 is another story.
The study was published in the journal Cell Death and Disease.